Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Ana Luisa Perdigoto Clear advanced filters

  • There are dynamic interactions between immune cells and β cells that lead to β cell destruction in the context of autoimmune diabetes. Here the authors show that TET2, a methylcytosine dioxygenase, can regulate this interaction and deletion of TET2 can prevent the autoimmune destruction of β cells in mice.

    • Jinxiu Rui
    • Songyan Deng
    • Kevan C. Herold
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-13

  • The first immune-targeted drug for type 1 diabetes (T1D), teplizumab, received regulatory approval by the US FDA in 2022. In this Review, Herold, Walker and colleagues examine the immune mechanisms that underpin T1D and provide an overview of immune-targeted strategies for T1D that are currently in development.

    • Kevan C. Herold
    • Thomas Delong
    • Lucy S. K. Walker
    Reviews
    Nature Reviews Immunology
    Volume: 24, P: 435-451